New results boost NuQ for lung and CRC
VolitionRx (N:VNRX) recently released data for NuQ in colorectal and lung cancer, 7 January 2016 which both exceeded results from previous trials. In colorectal cancer (CRC), the test when adjusted for age detected 91% of tumors with 90% specificity in its first completed prospective study, unlike previous retrospective studies. The company also released encouraging interim lung cancer data detecting 93% of tumors with 91% specificity using the NuQ test in combination with smoking history, which positions the test as one of the most accurate non-invasive lung cancer diagnostics.
Improved colorectal test results
VolitionRx recently released the results of a clinical study in which 121 patients referred to a hospital with symptoms of CRC underwent a panel of four NuQ tests. When adjusted for the age of the individual, the panel identified 21 of 23 patients with two false positives, for a sensitivity and specificity of 91% and 90% respectively. These surpass the historical sensitivity and specificity of the NuQ test of 81-84%/76-78% testing preserved samples and are comparable with results from Cologuard (92/87%).
To read the entire report Please click on the pdf File Below